小剂量甲状腺素对低T3代偿期肝硬化的影响

Clinical Effect of Low Dose Tetraiodothyronine in Hepatic Fibrosis Activity on Compensated Cirrhosis with T3 Degraded

目的探讨代偿期肝硬化甲状腺激素水平的变化及小剂量甲状腺素对低T1代偿期肝硬化患者肝纤维化的影响。方法60名伴有T3降低的代偿期肝硬化患者，随机分为两组，给予相同的保肝、营养支持治疗，治疗组另加左旋甲状腺素片25m#d，连续1个月，观察两组临床疗效、肝功能及肝纤维化指标的变化。结果治疗组同对照组临床疗效无差异，治疗组血清AST、ALT、血清透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原肽（PC-Ⅲ）、Ⅳ型胶原（C-Ⅳ）水平低于对照组，ALB无变化，A／G比值高于对照组。结论外源性甲状腺素对T3代偿期肝硬化患者能减轻肝纤维化的发展。

Objectives To investigate change of Tetraiodothyronine（TH） in serum on compensated cirrhosis with T3 degraded and observe the effect of TH in hepatic fibrosis activity, Methods Sixty patients were randomly divided into experimental group and control group. The patients in experimental group and control group received same treatment,including protecting hepatic function and nutritional support. TH were taken to experimental group with 25 mg/d for a month, clinical effect were estimated, Hepatic function and hepatic fibrosis activity were measured in serum on all patients when the treatment was over. Results In comparison with control group,the levels of AST,ALT,HA, LN,PC-Ⅲ and C-Ⅳ in serum were lower,the level of ALB was indiscriminate, and proportionality of A/G was higher in cirrhosis. Clinical effect was same in two groups. Conclusion The level of TH in serum was decreasing in compensation cirrhosis ,and additional TH can decrease hepatic fibrosis activity ,but can not improve clinical effect in short.